How should a 46-year-old woman with mildly elevated thyroid‑stimulating hormone (TSH) around 6 mIU/L and normal triiodothyronine (T3) be managed?

Management of Subclinical Hypothyroidism with TSH 5.81 mIU/L

Do not routinely treat this patient with levothyroxine; instead, repeat TSH and thyroid antibodies in 2-3 months and monitor at 6-12 month intervals thereafter. 1

Diagnostic Clarification

Your patient has subclinical hypothyroidism with TSH 5.81 mIU/L (mildly elevated) and normal T3 3.0. The critical missing piece is the free T4 level, which should be confirmed as normal to definitively diagnose subclinical hypothyroidism rather than overt disease.

Treatment Decision Framework

TSH 5.81 mIU/L Falls in the "Do Not Treat" Range

This TSH level sits squarely in the 4.5-10 mIU/L range where routine levothyroxine treatment is not recommended 1. The 2004 JAMA guidelines explicitly state that available data do not confirm clear-cut benefits for early therapy compared with watchful waiting 1. The 2012 AACE/ATA guidelines reinforce that the normal TSH upper limit is 4.12 mIU/L, but treating patients between this and 10 mIU/L lacks supporting data except in pregnancy 2.

Why Not Treat?

• No proven mortality or morbidity benefit: No studies demonstrate decreased morbidity or mortality with treatment in this TSH range 1
• Minimal progression risk: While progression to overt hypothyroidism is possible, many patients actually revert to normal TSH without treatment 3
• Treatment risks: 14-21% of treated patients develop subclinical hyperthyroidism, which carries cardiovascular and skeletal risks, particularly in postmenopausal women 1, 2
• Unclear symptom benefit: The likelihood of symptomatic improvement is small and difficult to distinguish from placebo effect 1

Specific Management Algorithm

Step 1: Confirm the Diagnosis (Now)

• Repeat TSH in 2-3 months with thyroid peroxidase antibodies (TPO-Ab) 4
• Ensure free T4 is documented as normal
• Rule out assay interference: Ask about biotin supplementation (can cause spurious results) 5
• Check for medications affecting absorption or TSH levels 2

Step 2: Risk Stratification

Check TPO antibodies when repeating TSH because:

• Positive TPO-Ab increases progression risk to overt hypothyroidism
• Helps predict which patients need closer monitoring 4, 6

Step 3: Ongoing Monitoring

• Repeat TSH every 6-12 months if it remains 4.5-10 mIU/L 1
• Monitor for symptom development
• No treatment unless TSH rises above 10 mIU/L or specific indications develop

Exceptions Where Treatment Would Be Indicated

Treat if TSH >10 mIU/L

If repeat testing shows TSH >10 mIU/L, levothyroxine therapy becomes reasonable due to higher progression risk (5% annually) 1

Treat if Specific Comorbidities Present

Consider treatment even with TSH 5-10 mIU/L if patient has:

• Coronary artery disease or heart failure (treatment is necessary in severe SCH with these conditions) 4
• Dyslipidemia (may be considered) 4
• Pregnancy or planning pregnancy (different thresholds apply; treatment indicated) 1, 7
• Symptomatic hypothyroidism with clear symptoms (trial therapy acceptable but continuation requires clear benefit) 1

Age Consideration

At 46 years old, she is not elderly (defined as ≥70 years), so age alone does not modify recommendations. Elderly patients generally should not be treated regardless of SCH severity 4, but this does not apply here.

Common Pitfalls to Avoid

1. Don't treat based on single TSH measurement: TSH varies up to 50% day-to-day 2; always confirm with repeat testing
2. Don't ignore biotin: This common supplement causes falsely low TSH and high T4/T3, potentially masking true hypothyroidism 5
3. Don't use different laboratories: Sequential testing should be from the same lab due to assay variability 5
4. Don't rush to treat symptoms: Hypothyroid symptoms are nonspecific; distinguishing true therapeutic effect from placebo is difficult 1
5. Don't overtarget TSH: If treatment is initiated, target mid-normal range, not low-normal, as this increases overtreatment risks 2

If Patient Insists on Treatment Trial

If the patient has symptoms she attributes to hypothyroidism, you may offer a several-month trial of levothyroxine 1. However:

• Set clear expectations that benefit is unlikely
• Continuation requires clear symptomatic benefit, not just TSH normalization
• Start low dose (25-50 mcg daily for a 46-year-old without cardiac disease)
• Reassess symptoms objectively at 2-3 months

The evidence strongly favors observation over treatment in this scenario, prioritizing avoidance of unnecessary medication risks over uncertain benefits.